A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma

Background: Tbo-filgrastim, biosimilar to filgrastim, was approved by the FDA in 2012 as a new drug due to the lack of a biosimilar approval pathway at time of submission. Like filgrastim, tbo-filgrastim is currently indicated for the treatment of neutropenia following chemotherapy; however, filgrastim is also indicated for mobilization of hematopoietic progenitor cells for autologous stem cell transplantation (ASCT) while tbo-filgrastim is not. In Europe, tbo-filgrastim carries all the indications that filgrastim does, however, no prospective studies have been completed comparing tbo-filgrastim and filgrastim for ASCT mobilization. Therefore, we conducted a single-institution randomized phase 2 trial. Objectives : 1) To compare peripheral blood (PB) CD34+ counts, CD34+ apheresis yield, toxicity, and post-ASCT engraftment in patients mobilized with tbo-filgrastim versus filgrastim. Methods: Participants were at least 18-years-old and had multiple myeloma (MM) or non-Hodgkin's Lymphoma (NHL). Those with impaired hematologic function and those who had undergone a previous ASCT mobilization were excluded. Participants were randomized (1:1) to tbo-filgrastim or filgrastim. Tbo-filgrastim/filgrastim (10mcg/kg) was administered daily for 5 days. On the evening of Day 4, plerixafor (0.24 mg/kg) was administered; apheresis (20L) was performed on Day 5. If a participant failed to achieve the target collection goal (5.0x106 cells/kg) on Day 5, he/she continued to receive daily tbo-filgrastim/filgrastim, plerixafor, and apheresis for a maximum of 3 additional days. Participants who subsequently underwent ASCT were followed for platelet and neutrophil engraftment. Statistics: PB CD34+ counts and CD34+ apheresis yields were compared using Mann-Whitney U, engraftment using log-rank. Results: At the time of abstract submission, corresponding with interim analysis 1, 51 participants were enrolled and 49 were evaluable for analysis; 24 received tbo-filgrastim, 25 filgrastim. The median age was 60 years (range 40-77); 63% (31) were male; 86% (42) had MM, 14% (7) NHL. Both treatment arms were similar in demographics and baseline blood counts. Post-mobilization PB CD34+ counts were similar between both arms. The median PB CD34+ count on day 4 (pre-plerixafor) was 20/mcL for tbo-filgrastim and 22/mcL for filgrastim (p=0.647); on Day 5 pre-apheresis it was for 94/mcL for tbo-filgrastim and 92/mcL for filgrastim (p=0.726). CD34+ apheresis yield was also similar; the median Day 5 CD34+/kg apheresis yield was 10.9x106 for tbo-filgrastim and 12.0x106 for filgrastim (p=0.889). Seventy-five percent of the tbo-filgrastim arm reached the collection goal after one day of apheresis, 76% of the filgrastim arm did (p=0.935). Ninety-six percent of patients on the tbo-filgrastim arm reached the goal in 4 or less days of apheresis, 92% of the filgrastim arm did (p=0.576). All patients treated collected > 2.0x106 cells/kg, the minimum required for ASCT, following < 2 days of apheresis. Both treatment arms had similar toxicity. Thirty-nine patients have subsequently undergone ASCT and evaluable for engraftment, 18 on the tbo-filgrastim arm and 21 on the filgrastim arm. The median interval of neutrophil engraftment for tbo-filgrastim was 12 days compared to 11 for filgrastim (p=0.178); the median interval of platelet engraftment was 17 days for both arms (p=0.238). Mobilization, collection, toxicity, and engraftment data are summarized in Table 1. Conclusion: Tbo-filgrastim appears to be similar to filgrastim for ASCT mobilization in patients with MM or NHL. Planned study enrollment is 100 evaluable patients; updated study results will be presented. | | Tbo-Filgrastim | Filgrastim | | ------------------------------------------------------- | --------------- | --------------- | | PB CD34+/mcl on Day 41 (median & range) | 20 (4-68) | 22 (1-115) | | PB CD34+/mcl on Day 5 (median & range) | 94 (18-187) | 92 (11-314) | | CD34+/kg x106 yield on Day 5 (median & range) | 10.9 (1.4-21.2) | 12.0 (1.3-28.4) | | CD34+/kg yield >2.0 on Day 5 | 96% | 92% | | CD34+/kg yield >5.0 on Day 5 | 75% | 76% | | CD34+/kg yield >2.0 in < 4 days | 100% | 100% | | CD34+/kg Yield >5.0 in < 4 days | 96% | 92% | | Post-ASCT Engraftment | | Days to Neutrophil Engraftment (median & range) | 12 (10-20) | 11 (10-13) | | Days to Platelet Engraftment (median & range) | 17 (13-23) | 17 (13-22) | Table 1. 1-Prior to plerixafor dose Disclosures Vij: Celgene, Onyx, Takeda, Novartis, BMS, Sanofi, Janssen, Merck: Consultancy; Takeda, Onyx: Research Funding. Abboud: Teva Phamaceutical: Research Funding.